TrippBio

Executive Summary

TrippBio is a Boston-based biotech company focused on developing novel antiviral therapies through drug repurposing. Its lead candidate, PanCytoVir™, is a host-targeted antiviral with both antiviral and anti-inflammatory properties, designed for respiratory viruses. By leveraging existing drugs with established safety profiles, TrippBio aims to reduce development risk and accelerate timelines. The company’s approach addresses a critical need for effective treatments against respiratory viral infections, including potential pandemic threats. TrippBio is currently in Phase 2 clinical development with PanCytoVir™. The company’s repurposing strategy may enhance the probability of success compared to novel compounds. Key upcoming catalysts include Phase 2 data readouts and potential strategic partnerships. With a focus on high-unmet-need indications, TrippBio represents an attractive opportunity in the antiviral space. However, as a private company, financial details and specific timelines remain undisclosed.

Upcoming Catalysts (preview)

• 2026-2027Phase 2 Interim Data Readout for PanCytoVir™45% success
• 2026-2027Strategic Partnership or Licensing Deal50% success